Kala is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for diseases of the eye. Kala has applied its AMPPLIFY® mucus-penetrating particle (MPP) Drug Delivery Technology to two ocular therapies, EYSUVIS™ (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to two weeks) treatment of signs and symptoms of dry eye disease and INVELTYS® (loteprednol etabonate ophthalmic suspension) 1% for the treatment of post-operative inflammation and pain following ocular surgery. The Company also has a pipeline of pre-clinical development programs targeted to address unmet medical needs, including both front and back of the eye diseases.
Company profile
Ticker
KALA
Exchange
Website
CEO
Mark Iwicki
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Kala Pharmaceuticals Security Corporation • Combangio, Inc. ...
KALA stock data
Latest filings (excl ownership)
8-K
Entry into a Material Definitive Agreement
19 Jan 23
424B5
Prospectus supplement for primary offering
19 Jan 23
8-K
Other Events
10 Jan 23
S-8
Registration of securities for employees
4 Jan 23
8-K
Entry into a Material Definitive Agreement
27 Dec 22
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
9 Dec 22
8-K
Entry into a Material Definitive Agreement
28 Nov 22
10-Q
2022 Q3
Quarterly report
8 Nov 22
8-K
Kala Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
8 Nov 22
8-K
Departure of Directors or Certain Officers
1 Nov 22
Transcripts
KALA
Earnings call transcript
2022 Q2
12 Aug 22
KALA
Earnings call transcript
2022 Q1
16 May 22
KALA
Earnings call transcript
2021 Q4
29 Mar 22
KALA
Earnings call transcript
2021 Q3
15 Nov 21
KALA
Earnings call transcript
2021 Q2
5 Aug 21
KALA
Earnings call transcript
2021 Q1
5 May 21
KALA
Earnings call transcript
2020 Q4
25 Feb 21
KALA
Earnings call transcript
2020 Q3
7 Nov 20
KALA
Earnings call transcript
2020 Q2
8 Aug 20
KALA
Earnings call transcript
2020 Q1
10 May 20
Latest ownership filings
Financial summary
| Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 52.64 mm | 52.64 mm | 52.64 mm | 52.64 mm | 52.64 mm | 52.64 mm |
| Cash burn (monthly) | (no burn) | 6.22 mm | 4.86 mm | 9.86 mm | 5.22 mm | 7.76 mm |
| Cash used (since last report) | n/a | 26.26 mm | 20.51 mm | 41.63 mm | 22.05 mm | 32.76 mm |
| Cash remaining | n/a | 26.39 mm | 32.13 mm | 11.02 mm | 30.59 mm | 19.88 mm |
| Runway (months of cash) | n/a | 4.2 | 6.6 | 1.1 | 5.9 | 2.6 |
Institutional ownership, Q3 2022
| 13F holders | Current |
|---|---|
| Total holders | 56 |
| Opened positions | 4 |
| Closed positions | 21 |
| Increased positions | 11 |
| Reduced positions | 16 |
| 13F shares | Current |
|---|---|
| Total value | 36.90 mm |
| Total shares | 21.47 mm |
| Total puts | 10.10 k |
| Total calls | 0.00 |
| Total put/call ratio | Infinity |
| Largest owners | Shares | Value |
|---|---|---|
| Blumenkranz Mark S. | 5.14 mm | $10.80 mm |
| Lagunita | 5.14 mm | $10.80 mm |
| Lagunita Biosciences | 5.14 mm | $10.80 mm |
| Vanguard | 1.19 mm | $263.00 k |
| BLK Blackrock | 787.25 k | $175.00 k |
| Samsara BioCapital | 601.16 k | $132.00 k |
| Board of Trustees of The Leland Stanford Junior University | 568.94 k | $126.00 k |
| Millennium Management | 557.96 k | $124.00 k |
| Geode Capital Management | 447.68 k | $99.00 k |
| Renaissance Technologies | 436.80 k | $97.00 k |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 4 Jan 23 | Bazemore Todd | Common Stock | Sell | Dispose S | No | Yes | 28.54 | 62 | 1.77 k | 14,835 |
| 4 Jan 23 | Bazemore Todd | Common Stock | Grant | Acquire A | No | No | 0 | 12,800 | 0.00 | 14,897 |
| 4 Jan 23 | Darius Kharabi | Common Stock | Grant | Acquire A | No | No | 0 | 9,525 | 0.00 | 15,439 |
| 4 Jan 23 | Trachtenberg Eric | Common Stock | Sell | Dispose S | No | Yes | 28.55 | 60 | 1.71 k | 11,495 |
| 4 Jan 23 | Trachtenberg Eric | Common Stock | Grant | Acquire A | No | No | 0 | 9,525 | 0.00 | 11,555 |
| 4 Jan 23 | Reumuth Mary | Common Stock | Sell | Dispose S | No | Yes | 28.54 | 60 | 1.71 k | 11,883 |
| 4 Jan 23 | Reumuth Mary | Common Stock | Grant | Acquire A | No | No | 0 | 9,525 | 0.00 | 11,943 |
| 4 Jan 23 | Brazzell Romulus K | Common Stock | Sell | Dispose S | No | Yes | 28.53 | 73 | 2.08 k | 18,536 |
| 4 Jan 23 | Brazzell Romulus K | Common Stock | Grant | Acquire A | No | No | 0 | 12,800 | 0.00 | 18,609 |
News
10 Short Squeeze Candidates To Watch This Week: Edible Garden, Getty Images And This Stock Moving Up 1,785 Places
30 Jan 23
12 Health Care Stocks Moving In Thursday's Intraday Session
26 Jan 23
Kala Pharmaceuticals, PaxMedica, Getty And Other Short Squeeze Stocks That Could Soar
23 Jan 23
12 Health Care Stocks Moving In Thursday's After-Market Session
19 Jan 23
Kala Pharmaceuticals, Getty Images And This Bitcoin Stock Top Short Squeeze Leaderboard: 10 Short Squeeze Stocks To Watch
17 Jan 23
Press releases
Thinking about buying stock in Novocure, Zai Lab, Kala Pharmaceuticals, Orchard Therapeutics, or CytomX Therapeutics?
5 Jan 23
Thinking about buying stock in Palisade Bio, Kala Pharmaceuticals, F-Star Therapeutics, Nuwellis, or TG Therapeutics?
30 Dec 22
Global Rheumatoid Arthritis Drugs Market Expected To Hit US$ 70 Billion By 2030
30 Dec 22
Thinking about buying stock in Baudax Bio, Kala Pharmaceuticals, GlycoMimetics, Pagaya Technologies, or Transcode Therapeutics?
29 Dec 22
Thinking about buying stock in Jounce Therapeutics, Kala Pharmaceuticals, Nano-X Imaging, F-Star Therapeutics, or Pagaya Technologies?
28 Dec 22